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Abstract Several lines of growth hormone (GH)-
overexpressing fish have been produced and analysed
for growth and fertility parameters. However, only few
data are available on the growth-promoting hormone
insulin-like growth factor I (IGF-I) that mediates most
effects of GH, and these are contradictory. Using
quantitative real-time RT-PCR, radioimmunoassay,
in situ hybridization, immunohistochemistry, and
radiochromatography we investigated IGF-I and IGF
binding proteins (IGFBPs) in an adult (17 months old)
transgenic (GH-overexpressing) tilapia (Oreochromis
niloticus). The transgenics showed an around 1.5-fold
increase in length and an approximately 2.3-fold
higher weight than the non-transgenics. Using radio-
immunoassay, the serum IGF-I levels were lower
(6.22 ± 0.75 ng/ml) in transgenic than in wild-type
(15.01 ± 1.49 ng/ml) individuals (P = 0.0012). Radio-
immunoassayable IGF-I in transgenic liver was 4.2-
times higher than in wild-type (16.0 ± 2.21 vs.
3.83 ± 0.71 ng/g, P = 0.0017). No hepatocytes in
wild-type but numerous hepatocytes in transgenic liver
contained IGF-I-immunoreactivity. RT-PCR revealed
a 1.4-times higher IGF-I mRNA expression in the liver
of the transgenics (10.51 ± 0.82 vs. 7.3 ± 0.49 pg/mg
total RNA, P = 0.0032). In correspondence, in situ
hybridization showed more IGF-I mRNA containing
hepatocytes in the transgenics. A twofold elevated
IGF-I mRNA expression was determined in the
skeletal muscle of transgenics (0.33 ± 0.02 vs.
0.16 ± 0.01 pg/mg total RNA, P < 0.0001). Both liver
and serum of transgenics showed increased IGF-I
binding. The increased IGFBP content in the liver may
lead to retention of IGF-I, and/or the release of IGF-I
into the circulation may be slower resulting in accu-
mulation of IGF-I in the hepatocytes. Our results
indicate that the enhanced growth of the transgenics
likely is due to enhanced autocrine/paracrine action of
IGF-I in extrahepatic sites, as shown here for skeletal
muscle.
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Introduction
Insulin-like growth factor I (IGF-I) is a potent
mitogenic hormone that induces growth and differ-
entiation in a variety of target organs (Jones and
Clemmons 1995; Reinecke and Collet 1998; Butler
and LeRoith 2001). In mammals, IGF-I is mainly
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produced in the liver which is the principal source of
endocrine IGF-I. The primary stimulus for the
synthesis and secretion of liver IGF-I is growth
hormone (GH) released from the anterior pituitary
(Reinecke et al. 2005).
Like in mammals, the major site of IGF-I gene
expression in bony fish is liver (Duan 1998; Reinecke
et al. 2005; Wood et al. 2005). High-affinity GH
binding sites have been characterized in salmon and
tilapia liver (Gray et al. 1992; Ng et al. 1992;
Shepherd et al. 1997). In accordance, GH injections
promoted liver IGF-I mRNA expression in salmonids
and tilapia (e.g. Duan et al. 1993a; Moriyama 1995;
Shamblott et al. 1995; Duguay et al. 1996; Shepherd
et al. 1997; Guille´n et al. 1998; Kajimura et al. 2001;
Vong et al. 2003) and raised IGF-I plasma levels in
salmonids, seabream and tilapia (e.g. Moriyama
1995; Shamblott et al. 1995; Guille´n et al. 1998;
Moriyama et al. 2000; Kajimura et al. 2001), which
was accompanied by an increase in growth (Guille´n
et al. 1998). Similarly, GH also stimulates the
expression of IGF-I mRNA in primary hepatocyte
cultures of bony fish, such as salmonids (Duan et al.
1993a, b; Shamblott et al. 1995; Pierce et al. 2005)
and tilapia Oreochromis mossambicus (Schmid et al.
2000). In adult Coho salmon, continuous infusion of
bovine IGF-I increased growth rate and weight gain
(McCormick et al. 1992), and plasma IGF-I levels
and growth rate were significantly correlated in O.
mossambicus (Kajimura et al. 2001; Uchida et al.
2003).
Several groups have produced different lines of
transgenic fish (e.g. Devlin et al. 2000; Maclean et al.
2002; Rocha et al. 2004). Among the transgenic fish
those carrying exogenous GH gene constructs con-
stitute the majority. The obvious reason for this focus
of interest is to improve fish growth in aquacultural
food production (Zbikowska 2003). Mainly salmo-
nids (Du et al. 1992; Devlin et al. 1994, 2000;
Sundstrom et al. 2004), carp (Zhang et al. 1990),
tilapia (Martinez et al. 1996; Rahman et al. 1998),
and sea bream (Lu et al. 2002) have been used for
genetically induced growth enhancement. On the
other hand, GH-overexpressing fish are also consid-
ered as excellent models to study gene regulation and
development (Amsterdam and Becker 2005). How-
ever, investigations on transgenic fish have almost
exclusively dealt with growth parameters, fertility,
and body and organ integrity (Maclean et al. 2002;
Sundstrom et al. 2004).
The above referred studies demonstrate the stim-
ulating action of GH on IGF-I-mediated growth in
bony fish either by bolus injections of GH or by
adding GH to the medium of primary hepatocyte
cultures and, thus, deal with short-term effects of GH.
In contrast, only one study has dealt with IGF-I in
transgenic GH-overexpressing fish. In Coho salmon
Oncorhynchus kisutch IGF-I serum levels were
determined and gave contradictory results (Devlin
et al. 2000): in one experiment they were slightly
enhanced and in another slightly reduced. In order to
investigate whether the severe enhancement in body
growth in GH-overexpressing fish may be due to
endocrine (liver-derived) IGF-I and/or enhanced IGF-
I expression in skeletal muscle we used a transgenic
GH-overexpressing and age-matched wild-type tila-
pia (Oreochromis niloticus). The following parame-
ters were analysed: (1) the expression level of IGF-I
mRNA in liver and skeletal muscle using quantitative
real-time PCR, (2) the concentration of IGF-I peptide
in liver and serum by RIA, (3) the localization of
IGF-I in liver at the mRNA level by in situ hybrid-
ization and at the peptide level by immunohisto-
chemistry, and (4) the IGF-I binding proteins
(IGFBPs) in liver and serum by radiochromatogra-
phy.
Material and methods
Animals
The transgenic fish used in these experiments have
been previously produced from crosses between a
wild-type female O. niloticus and a G1 transgenic
male. This line of growth-enhanced tilapia (C86)
carries a single copy of a Chinook salmon Oncorhyn-
chus tshawytscha GH gene spliced to an ocean pout
Macrozoarces americanus antifreeze promoter (OP-
AFPcsGH) co-ligated with a carp beta actin/lacZ
reporter gene construct, integrated into the tilapia
genome (Rahman et al. 1998). Tilapia of the C86
strain and the non-transgenic siblings were bred at the
University of Southampton. The fish were kept in
fresh water tanks at 27 ± 18C under a 12 h/12 h light/
dark cycle and fed to satiation. Adult (17 months)
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transgenic (TG) and wild-type (WT) fish were used
for the experiments. Fish were anaesthetized with 2-
phenoxy-ethanol (Sigma, St Louis, MO, USA) added
to water, measured in weight and length, and the
tissue samples excised. Principles of animal care and
specific national laws were followed.
Detection of transgene
The transgenic or non-transgenic state of the indi-
viduals was detected by RT-PCR followed up by
Southern Blotting. For PCR amplification an approx-
imately 3 mm · 2 mm fin clip was taken from the
caudal fin and immediately frozen in liquid nitrogen.
Genomic DNA was isolated. The standard procedures
for isolation and purification of DNA (Rahman and
Maclean 1992) and subsequent PCR and Southern
Blotting were performed as described before (Rah-
man et al. 1998).
Tissue sampling and extraction
Liver (n = 10 TG, n = 10 WT) and skeletal muscle
(n = 6 TG, n = 6 WT) specimens for RT-PCR were
excised and immediately transferred into 1.5 ml of
the RNA-preserving reagent RNAlaterTM (Ambion,
Austin, USA). The samples were kept at 48C to
promote inactivation of RNAses and later stored at
208C until RNA isolation. Total RNA was extracted
using TRIzol reagent (GibcoBRL), treated with 1 U
of RQ1 RNAse-free DNase (Catalys AG, Wallisellen,
Switzerland), resuspended in DEPC-treated H2O and
stored at 808C.
Absolute quantification of liver and skeletal
muscle IGF-I gene expression by real-time PCR
Absolute quantification of liver and skeletal muscle
IGF-I mRNA was performed as already described
(Caelers et al. 2004). In brief, based on the gene
sequences of O. mossambicus IGF-I (Reinecke et al.
1997), and O. niloticus b-actin as a housekeeping
gene (Hwang et al. 2003), tilapia specific primers and
probes for real-time RT-PCR were designed with the
Primer Express software version 1.5 (PE Biosystems,
Foster City, CA, USA). To create templates for
in vitro transcription, a T7 phage polymerase pro-
moter gene sequence was added by primer extension
to the 50end of the antisense primers using conven-
tional RT-PCR of O. niloticus liver total RNA. For
cDNA synthesis, 5 mg RNA were annealed with 1 mM
poly(dT) primer (50-CCTGAATTCTAGAGCT-
CAT(dT17)-30) for 5 min at 708C. The RNA/primer
mix was incubated for 1 h at 378C with 10 mM
dNTPs and 100 U M-MLV-RTase (Promega) in 1·
buffer. One microlitre aliquots of cDNA were added
to 50 ml PCR reaction using the Thermo-StartTM PCR
Master Mix (Abgene, NY, USA). Amplification
conditions were optimized for a Stratagene RoboCy-
cler Gradient 40: 1 cycle 10 min at 948C, 1 min at
608C, 2 min at 728C; 40 cycles 1 min at 948C, 1 min
at 608C, 2 min at 728C; final extension 10 min at
728C. PCR products including the T7 promoter gene
sequence were sequenced and visualized on a 2.5%
agarose gel. Standard cRNAs were generated by
in vitro transcription using the T7-MEGAshort-
scriptTM Kit (Ambion), analysed by photospectrom-
etry and UV-shadowing, and quantified by
photospectrometry and dot blot. Defined amounts at
tenfold dilutions were subjected to real-time PCR
using a one-Step-RT-PCR Mastermix (Applied Bio-
systems, Rotkreuz, Switzerland). RT-step (488C,
30 min) and denaturation step (958C, 10 min) were
performed followed by 40 cycles (958C, 15 s; 608C,
1 min) in a single tube using ABI PRISMTM 7700
Sequence Detection System Perkin Elmer (Applied
Biosystems). Standard curves were generated based
on the linear relationship between CT value and
logarithm of the starting amount. For measurements,
tenfold diluted defined amounts of standard cRNA
and 10 ng of total RNA were subjected in parallel to
real-time PCR under the same experimental settings.
To calculate absolute amounts the different lengths of
cRNA and mRNA were considered by a correction
factor determined by division of lengths of IGF-I
mRNA and cRNA (546 nt/70 nt = 7.8).
Peptide extraction of serum and liver
Blood (n = 5 TG, n = 5 WT) was taken with a 1 ml
heparinized syringe from the caudal vein and col-
lected in sterile 0.5 ml tubes. The blood was
centrifuged at 13,000 rpm for 15 min at 48C and
the serum removed and stored at –208C until use. 1 g
of liver (n = 5 TG, n = 5 WT) was homogenized with
5 ml 0.1 M sodium phosphate buffer (pH 7.0) and
centrifuged at 10,000g for 15 min at 48C. The
supernatant was removed with a Pasteur pipette,
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deep-frozen immediately, and stored at -208C until
use. To dissociate IGF-I from the binding proteins,
acid–ethanol extraction was performed as already
described. In brief, 40 ml of serum and liver
homogenate, respectively, was thoroughly mixed
with 160 ml of an acid–ethanol extraction mix
(87.5% ethanol, 12.5% 2 M HCl, v/v) and incubated
for 30 min at room temperature. After neutralization
with 0.885 M Tris base, the extracts were centrifuged
at 13,000 rpm at 48C for 10 min. 50 ml of the
supernatant was used for the IGF-I radioimmunoas-
say.
Radioimmunoassay in serum and liver
Serum and liver IGF-I was measured using the Fish
IGF-I RIA kit for the tilapia O. mossambicus (GroPep
Pty Ltd., Adelaide, Australia) with recombinant
tilapia IGF-I as tracer and standard according to the
protocol of the manufacturer.
Radiochromatography for IGFBPs in serum and
liver
Radiochromatography was performed as described
earlier (Zapf et al. 1975, 1989). Briefly, 0.2 ml of
pooled serum or liver homogenate was diluted with
0.3 ml of Dulbecco’s phosphate-buffered saline, pH
7.4, containing NaN3 and 500 U of Trasylol (Bayer,
Germany), and incubated for 24 h at 48C with 125I-
labelled tilapia IGF-I (2.5 · 105 CPM, GroPep Ltd.).
The mixture was run through a Sephadex G-200
column (2.1 cm · 70 cm) preequilibrated with
Dulbecco’s buffered saline, pH 7.4, and the radioac-
tivity of the collected fractions (2.5 ml) was counted
in a gamma-counter.
Preparation of probes for in situ hybridization
Probes were prepared as described (Schmid et al. 1999;
Berishvili et al. 2006a, b). In brief, total RNA from
tilapia liver was extracted with the Ultraspec Extrac-
tion Kit (ams, Lugano, Switzerland). For cDNA
synthesis 5 mg RNA was annealed with 1 mM of a
poly(dT) primer (50 CCTGAATTCTAGAGCT-
CAT(dT17) 30) for 3 min at 708C. The RNA/primer
mix was incubated for 1 h at 378C with 15 mM dNTPs
and 10 U AMV-RTase (Pharmacia, Switzerland) in 1·
reaction buffer (50 mM Tris–HCl/pH 8.3, 40 mM KCl,
6 mM MgCl2). One microlitre cDNA was incubated
with 1 mM of sense (50-GTCTGTGGAGAGC-
G A G G C T T T - 3 0) a n d a n t i s e n s e ( 5 0-
AACCTTGGGTGCTCTTGGCATG-30) primers
corresponding to the B- and E-domain, 200mM dNTPs,
and 1 U Taq-polymerase (Pharmacia) in 1· incubation
buffer (10 mM Tris–HCl/pH 8, 50 mM KCl, 1.5 mM
MgCl2, 0.001 % gelatine). The amplification program
was optimized for a Stratagene RoboCycler Gradient
40:1 cycle 10 min at 948C, 1 min at 598C, 2 min at
728C; 30 cycles 1 min at 948C, 1 min at 598C and 2 min
at 728C followed by final extension for 5 min at 728C.
PCR fragments were separated on a 2% agarose gel and
eluted by the Gel Extraction Kit QIAquick (Qiagen,
Switzerland). Thereafter, the PCR products were
cloned in a pCR-Script SK(+) cloning vector using a
kit (Stratagene, Heidelberg, Germany). Plasmids con-
taining the gene sequence fragments were sequenced
(Microsynth, Switzerland) and the sequences com-
pared to database. The plasmids containing the specific
inserts of IGF-I (207 bp) were used as templates for the
synthesis of digoxigenin (DIG)-labelled RNA probes.
Linearization was performed with EcoRI for T3- and
NotI for T7-polymerase-driven transcription. One
microgram of linearized plasmids was transcribed
in vitro in the presence of DIG-UTP from T3 and T7
promotors to obtain antisense and sense (negative
control) probes. Integrity of probes and efficiency of
labelling were confirmed by dot blot and gel electro-
phoresis including blotting and incubation with anti-
body. Specificity of the probes has been demonstrated
previously (Schmid et al. 1999; Berishvili et al. 2006a).
In situ hybridization
Liver preparations (n = 3 WT, n = 3 TG) were fixed
by immersion with 4% buffered formalin for 4 h at
room temperature. Specimens were dehydrated in
ascending series of ethanol and routinely embedded
in paraplast (588C). Four micrometre sections were
mounted on Super Frost Plus slides (Menzel-Gla¨ser,
Germany) and dried overnight at 428C. After dewax-
ing and rehydration, the sections were postfixed with
4% paraformaldehyde and 0.1% glutaraldehyde in 1·
PBS. In situ hybridization was performed as previ-
ously described (Schmid et al. 1999; Berishvili et al.
2006a, b). The following steps were carried out with
DEPC-treated solutions in a humified chamber. The
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sections were digested with 0.02% proteinase K in
20 mM Tris–HCl/pH 7.4, 2 mM CaCl2 for 10 min at
378C. Thereafter, sections were treated with 1.5%
triethanolamine and 0.25% acetic anhydride for
10 min at room temperature and incubated with
50 ml prehybridization solution per section for 3–4 h
at 548C. Hybridization was performed overnight at
548C with 30 ml of hybridization buffer containing
10 ng of sense or antisense probe previously dena-
turated for 5 min at 858C. Slides were washed for
15 min at room temperature in 2· SSC, and for
30 min at the specific hybridization temperature at
descending concentrations of SSC (2·, 1·, 0.5·,
0.2·). The alkaline-phosphatase-coupled anti-DIG
antibody was diluted 1:4,000 in 1% blocking reagent
(Roche-Diagnostics) in buffer P1 and sections were
incubated for 1 h at room temperature in the dark.
After washing twice in P1 for 15 min, sections were
treated with buffer P3, 5 mM levamisole, and NBT/
BCIP stock solution (Roche Diagnostics). Colour
development was carried out overnight at room
temperature and stopped by rinse in tap water for
15 min. Sections were mounted with glycergel and
photographed with a Zeiss Axioscope using the
Axiovision software 3.1. (Zeiss, Zu¨rich, Switzerland).
Immunohistochemical technique
Specimens for immunohistochemistry (n = 3 WT,
n = 3 TG) were immersed in Bouin’s solution without
acetic acid for 4 h at room temperature. Specimens
were dehydrated in ascending series of ethanol and
routinely embedded in paraplast (588C). Sections
were cut at 4 mm, mounted onto glass slides and dried
overnight at 428C. After dewaxing and rehydration
unspecific binding was reduced by treatment with
PBS (pH 7.4) containing 2% bovine serum albumine
for 30 min at room temperature. Thereafter, the
sections were incubated overnight with the rabbit
antiserum 116 raised against human IGF-I (1:400)
and washed repetitively in PBS. This antiserum
specifically also stains IGF-I in fish as shown by
absorption experiments (Reinecke et al. 1997; Sch-
mid et al. 1999; Berishvili et al. 2006a, b). The IGF-I
antiserum was detected by incubation with biotiny-
lated goat anti-rabbit IgG (Bioscience Products,
Emmenbru¨cke, Switzerland, 1:100) for 30 min at
room temperature. After repetitive rinsing in PBS, the
reactions were visualized with fluorescein-isothiocy-
anate-conjugated streptavidin (Bioscience Products,
1:100) for 30 min at room temperature in the dark.
Sections were mounted with glycergel and photo-
graphed with a Zeiss Axioscope using the Axiovision
software 3.1.
Statistical analysis
Statistical analysis of the data was performed with a
GraphPad Prism 4 program. This included a Mann–
Whitney-U-test with a significance level of 5%. All
data are expressed as means ± SEM.
Results
Fish size and weight
The 17-month old transgenic fish showed an approx-
imately 1.5-fold increase in head–tail length when
compared to their non-transgenic siblings (28.7 ± 8.3
vs. 18.5 ± 6.2 cm). The mean weights of the
transgenics were around 2.3-fold higher than those
of their non-transgenic siblings (415.6 ± 98 g and
184 ± 64 g, respectively).
Measurement of IGF-I peptide and mRNA
Using radioimmunoassay, the serum IGF-I levels
were lower (6.22 ± 0.75 ng/ml) in transgenic than in
wild-type (15.01 ± 1.49 ng/ml) individuals
(P = 0.0012) (Fig. 1a). As measured by the same
radioimmunoassay, the IGF-I concentration in liver
amounted to 16.0 ± 2.21 ng/g in transgenics and to
3.83 ± 0.71 ng/g in wild-type animals (P = 0.0017)
(Fig. 1b). Real-time PCR revealed a 1.4-times higher
IGF-I mRNA expression in the liver of the transgen-
ics (10.51 ± 0.82 vs. 7.3 ± 0.49 pg/mg total RNA,
P = 0.0032, Fig. 1c) and a twofold elevated IGF-I
mRNA expression in the skeletal muscle (0.33 ± 0.02
vs. 0.16 ± 0.01 pg/mg total RNA, P < 0.0001,
Fig. 1d).
Localization of IGF-I mRNA and peptide
In situ hybridization with antisense DIG-labelled
RNA probe specific for tilapia IGF-I revealed
positive responses in liver whereas the sense RNA
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probe (negative control) showed no signals. In liver
from non-transgenic tilapia, IGF-I mRNA occurred in
numerous hepatocytes which were distributed in
clusters throughout the parenchyma (Fig. 2a). Liver
from transgenic individuals exhibited a higher degree
of labelled cells. This was especially pronounced
around the veins where numerous IGF-I mRNA
containing hepatocytes were present (Fig. 2b).
In the liver of wild-type tilapia no IGF-I immu-
noreactivity was observed in hepatocytes (Fig. 2c). In
contrast, numerous hepatocytes in transgenic liver
contained IGF-I-immunoreactivity (Fig. 2d).
Determination of IGFBPs in serum and liver
Radiochromatography of serum from wild-type and
transgenic tilapia gave two main radioactive peaks
around fraction 61 and fraction 85. In serum, the first
peak, an IGF-binding peak corresponding to a
molecular mass of 40–50 kDa, was about 1.6-fold
higher in the transgenic than in the wild-type fish
(Fig. 3a) as determined by planimetry. The second
peak representing unbound 125I-IGF-I tracer was
slightly higher for the wild-type serum, which is in
line with the observed decreased binding of the tracer
Fig. 1 (a, b) IGF-I peptide concentrations in serum (a) and
liver (b) were determined by a species-specific RIA. IGF-I
mRNA in liver (c) and muscle (d) were absolutely quantified
by real-time PCR. Columns give mean values of 5 (a, b), 10 (c)
and 6 (d) individuals and bars give SEM. WT wild-type, TG
transgenics. Significance levels in Mann–Whitney-U-test:
*P = 0.0032; **P = 0.0012, P = 0.0017, ***P < 0.0001
Fig. 2 IGF-I mRNA expression (a, b) and IGF-I immunore-
activity (c, d) in wild-type (a, c) and transgenic (b, d) tilapia
liver. In situ hybridization was performed with antisense DIG-
labelled RNA probe specific for tilapia IGF-I. Immunofluores-
cence used an IGF-I specific antiserum. In liver from wild-type
tilapia, IGF-I mRNA is detected in numerous hepatocytes
throughout the parenchyma (a) but no IGF-I peptide (c) is
found. In liver from transgenic individuals, numerous IGF-I
mRNA containing hepatocytes occur (b) and numerous
hepatocytes contain IGF-I-immunoreactivity (d). Bar (a, b)
100 mm, bar (c, d) 20 mm
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in the wild-type fish. The 40–50 kDa binding peak
disappeared when preincubation of the sera with the
tracer was performed in the presence of excess cold
IGF-I (not shown) indicating that binding was
specific. At the same time, the peak of unbound
tracer increased due to the inhibition of binding. Two
minor peaks around fractions 34 and 48 preceded the
40–50 kDa binding peak (Fig. 3a). Similar to the
latter, the peak around fraction 48 was displaced by
cold IGF-I, but its height was not essentially different
in wild-type and transgenic serum. In contrast, the
radioactive peak around fraction 34 was not displaced
by cold IGF-I indicating non-specific binding.
In the liver homogenate (Fig. 3b) a broader
binding peak (a ‘‘shoulder’’ between fractions 57
and 70) was observed that was again higher (about
1.7-fold) in the transgenic than in the wild-type
tilapia, whereas the reverse was true for the peak
representing unbound tracer. Also here, binding
disappeared in the presence of cold IGF-I (not
shown). The small peak around fraction 48 observed
in serum was not present in liver homogenate.
Discussion
When compared to their non-transgenic siblings
neither the whole phenotype nor the inner organs of
the transgenic tilapia of the C86 strain used here
exhibited any obvious abnormalities (Maclean et al.
2002; Caelers et al. 2005). Food conversion effi-
ciency was about 20% better in the transgenics and
these turned out to be more efficient utilizers of
protein and energy (Rahman et al. 1998). This is
reflected by the 2.3-fold higher mean body weight
and the 1.5-fold higher mean body length of the 17-
month old transgenics investigated.
According to real-time PCR and in situ hybridiza-
tion IGF-I was highly expressed in wild-type tilapia
liver. These results correspond to those of previous
PCR and Northern blot studies (e.g. Duan et al.
1993a, b; Duguay et al. 1996; Vong et al. 2003;
Caelers et al. 2004) and studies using in situ hybrid-
ization (Schmid et al. 1999; Berishvili et al. 2006b)
which have also reported a high content of IGF-I
mRNA in bony fish liver. Despite the expression of
IGF-I mRNA, no IGF-I-immunoreactive hepatocytes
could be observed. Earlier studies have also failed to
detect IGF-I-immunoreactivity in bony fish hepato-
cytes (Richardson et al. 1995; Reinecke et al. 1997).
Because the same antiserum from the latter study
detects IGF-I in numerous other organs of the tilapia
(Reinecke et al. 1997; Schmid et al. 1999; Berishvili
et al. 2006a, b) as well as in hepatocytes of the
transgenics (this study), the negative result cannot be
explained by the failure of the anti-mammalian IGF-I
antiserum to crossreact with fish, as discussed by
Plisetskaya (1998). Moreover, like in fish liver, IGF-
I-immunoreactivity could not be localized in rat liver
but was detectable only after pretreatment with
colchicine (Hansson et al. 1988). Thus, it is reason-
able to assume that IGF-I after synthesis is rapidly
released from the hepatocytes into the circulation
(Reinecke et al. 1997; Plisetskaya 1998).
In the present study, radioimmunoassayable IGF-I
in wild-type tilapia liver amounted to about 3.8 ng/g
(0.5 pmol/g). Until now, no results have been
Fig. 3 Radiochromatography of a serum and b liver homog-
enate from wild-type (blue curve) and transgenic (red curve)
tilapia. (a) The peak around fraction 61 corresponds to a
molecular mass of 40—50 kDa. It is preceded by two minor
peaks around fractions 34 and 48. The peak around fraction 85
represents unbound 125I-IGF-I tracer. (b) The binding peak
(‘‘shoulder’’) elutes between fractions 57 and 70. The small
peak around fraction 48 observed in serum (a) is not present in
liver (b). CPM counts per minute
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reported for fish liver IGF-I measured with a species-
specific RIA. A significantly (about fourfold) higher
level of IGF-I was found in the liver of transgenics
(16.0 ng/g; 2.1 pmol/g). This is paralled by the
detection of IGF-I-immunoreactive hepatocytes in
transgenic liver which were not observed in wild-
type, as well as by the increase in IGF-I mRNA
expression as revealed by RT-PCR and in situ
hybridization. Because the latter results may also
indicate a higher release of IGF-I into the circulation
the level of IGF-I in serum was determined. In wild-
type individuals it amounted to 15 ng/ml (*2 pmol/
ml) whereas in the transgenics it was 6.2 ng/ml
(0.82 pmol/ml). Comparison of the serum IGF-I
levels published for diverse bony fish shows a broad
range. The serum IGF-I concentration in wild-type O.
niloticus as measured here (15 ng/ml) is lower than
that reported in two previous studies on another
tilapia species, O. mossambicus (150 ng/ml, Riley
et al. 2002; 120 ng/ml, Uchida et al. 2003), but
consistent with recent data on O. mossambicus
(*20 ng/ml, Fiess et al. 2007) obtained under similar
rearing conditions (288C, freshwater, feeding) as used
here, and on rainbow trout (11.5 ng/ml, Gabillard
et al. 2003), brown trout (42.2 ng/ml, Ban˜os et al.
1999), Atlantic (53.1 ng/ml, Dyer et al. 2004) and
Coho salmon (7.5–14 ng/ml, Shimizu et al. 1999;
25.9 ng/ml, Shimizu et al. 2000; 45.2–85 ng/ml,
Moriyama 1995). In Coho salmon (Shimizu et al.
2003) and gilthead seabream (Mingarro et al. 2002),
plasma IGF-I levels changed with the seasons and
were higher in fed fish reared in a warm environment
(10–15 ng/ml) than in starved fish reared in the cold
(5–9 ng/ml, Larsen et al. 2001). In several salmonids,
liver IGF-I mRNA and/or plasma IGF-I levels were
related to environmental temperature (Gabillard et al.
2003; Larsen et al. 2001; Beckman et al. 1998). The
largely varying serum IGF-I levels in bony fish may,
thus, be due to species differences but may as well
reflect physiological parameters such as nutritional
status, seasons and environmental temperature (Rei-
necke and Collet 1998; Duan 1998; Reinecke et al.
2005).
As a first step towards identifying specific IGF-I
binding (IGF binding proteins) in tilapia serum and
liver we used incubation with 125I-IGF-I and
subsequent gel filtration at neutral pH (radiochroma-
tography). The main 125I-IGF-I binding peak of
tilapia serum eluted at the same position
(40–50 kDa) as in human serum (Zapf et al. 1975).
In human serum, this peak contains all six IGFBPs,
BP-1 to BP-6 (Zapf 1995). It is likely that the five
IGFBPs detected in fish serum so far (Duan and Xu
2005; Shimizu et al. 2005; Kelley et al. 2002, 2006)
are also located in this binding complex. Serum of the
transgenics bound more tracer than wild-type serum.
The height of the binding peak is determined by two
factors, the amount of binding protein and its IGF
content. Increased binding of 125I-IGF-I in the
transgenic serum could therefore be due to its lower
IGF-I concentration resulting in a greater residual
binding capacity or to a higher IGFBP concentration.
In agreement with the increased binding of 125I-IGF-I
in the serum of the transgenic (GH-overexpressing)
tilapia, short-term application of GH has been shown
to up-regulate the BP serum levels in Coho salmon
(Shimizu et al. 1999; Kelley et al. 1992), striped bass
(Siharath et al. 1995) and tilapia (O. mossambicus;
Park et al. 2000).
Whereas the radiochromatographic pattern of
human serum displays an IGF binding peak at
150 kDa (Zapf et al. 1975) consisting of a ternary
complex of IGFBP-3, IGF-I and -II, and an acid-
labile subunit (ALS, Baxter et al. 1989), the tested
tilapia serum showed only a minor binding peak in
the 150 kDa region. Whether this peak corresponds to
the ternary complex of mammalian serum is not clear.
However, no evidence for a ternary complex has so
far been obtained in fish serum (Kelley et al. 2006).
In contrast to serum, the protein-bound radioac-
tivity in tilapia liver homogenate eluted as a relatively
broad shoulder. It was shifted towards the peak of
non-bound tracer and, thus, apparently contained also
IGFBPs of smaller molecular weight or IGFBP
degradation products. The observed increased bind-
ing of tracer in transgenic liver is compatible with a
greater binding protein content than in wild-type liver
because the IGF-I concentration in the transgenic
liver was higher and binding capacity would therefore
be expected to be lower.
In GH-overexpressing Coho salmon, IGF-I serum
levels varied (Devlin et al. 2000): they were either
slightly enhanced or slightly reduced. Our finding
that the IGF-I serum levels in the growth-enhanced
transgenic tilapia were significantly by 60% lower
than in wild-type fish, despite increased IGF-I mRNA
expression and peptide levels in liver, was unex-
pected. This observation appears to be in contrast to
486 Transgenic Res (2007) 16:479–489
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results obtained in O. mossambicus demonstrating
that body length and mass are positively correlated
with the plasma IGF-I concentration (Kajimura et al.
2001; Uchida et al. 2003). Moreover, a clear corre-
lation between individual serum IGF-I levels and
growth rates has been established in Coho salmon
(Pierce et al. 2001). How could the lower IGF-I
serum levels in the transgenic animals be explained?
The increased content of IGFBPs in the liver of the
transgenics may lead to retention of IGF-I by these
BPs. This is further supported by the finding that
IGF-I-immunoreactivity was present in hepatocytes
of transgenic but not of wild-type liver.
In addition then, the question arises why trans-
genic tilapia have an approximately 1.5-fold greater
body length and a 2.3-fold higher body weight than
the wild-type despite lower serum IGF-I. Recent
studies using the Cre/loxP recombination system to
delete the IGF-I gene exclusively in the liver of mice
(Sjo¨gren et al. 1999; Yakar et al. 1999) underline the
potential importance of local IGF-I production for
growth. Despite deletion of liver IGF-I mRNA
expression and largely reduced levels of circulating
IGF-I, the animals did not show any obvious
impairment of postnatal body growth. Similarly, in
the transgenic tilapia, IGF-I in extrahepatic sites may
determine the growth rate. This has been shown here
to be true for skeletal muscle that is essentially
involved in growth. Enhanced growth therefore
seems to be caused by higher tissue levels of IGF-I
under the influence of the GH transgene and thus by
autocrine/paracrine actions of IGF-I.
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